We track where pharmaceutical demand is quietly concentrating — the molecules the industry is starting to build around, well before any of it reaches a headline. Here's the current picture, and it's a clear one.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
What we're seeing right now
Roughly 400 compounds are accelerating this week. The center of gravity is unambiguous: oncology is about 41% of the list, and anti-infectives about 16% — a smaller block that, surprisingly, carries two of the sharpest signals on the whole board (both get their own post in this series). One more surprise sits in the targets: the single most-pursued protein is TNF-alpha, and the second is a bacterial enzyme — not where anyone expects the money to be moving.
Why we trust it: the top of the list is full of molecules hitting a decisive milestone
The fastest way to fool yourself with any signal is to never check it against reality. So here's the check. The molecules at the very top of our list aren't obscure — they're the ones hitting a decisive, public milestone right now, whether an approval or a pivotal trial readout:
- Lazertinib — FDA-approved in August 2024 (as Lazcluze, with amivantamab) for EGFR-mutated lung cancer. [1]
- Fenebrutinib — in November 2025, the first BTK inhibitor to post positive Phase 3 results in both relapsing and primary-progressive multiple sclerosis. [2]
- Doravirine — approved with islatravir as IDVYNSO, a once-daily, tenofovir-free HIV regimen. [3]
We're not claiming to have called these approvals — this is a snapshot from this month. The point is stronger: our list independently surfaces the exact molecules the market is validating, with no knowledge of anyone's regulatory calendar. That's the calibration. And it means the rest of the list — the compounds climbing the same curve that haven't had their moment yet — is worth reading as a genuine leading indicator.
Why the lead time exists
The head start isn't magic; it's structural. A drug takes on the order of a decade to travel from first synthesis to approval, and it costs well over a billion dollars along the way. Most candidates that begin that journey never finish it — the attrition is brutal, and the survivors carry the cost of everything that failed alongside them. That economics forces a discipline: a company commits real chemistry, real money, and real people to a molecule long before it will ever say so publicly. And the very first thing it does to protect that commitment is file a patent.
That patent is the earliest public artifact of a program. It is filed near the start of the journey — to fence off the molecule before anyone talks about it — and by law it doesn't become public until roughly eighteen months after filing. So there is a structural delay baked into the record: by the time a program reaches a headline, a Phase 3 readout, or an approval, the paper trail it left behind is already years old. Read that trail in aggregate, and you're watching decisions the market won't price for a long time.
This is the difference between a lagging indicator and a leading one. Sales figures, approvals, and analyst upgrades are lagging — they tell you what already happened, and by then the position is crowded and the value is priced in. Early R&D activity is leading — it tells you what an industry is deciding to build, at the moment the decision is made and years before the outcome is known. Almost everyone in the market reads the lagging signals because they are easy to read. The advantage sits with whoever is willing to read the leading ones.
Reading the therapeutic map
The shape of the list is as informative as its length. Oncology's dominance — about 41% of everything accelerating — is exactly what a decade of scientific and financial gravity would predict. It's where the biology has opened up, where the capital has pooled, and where the largest number of shots on goal are being taken at once. That concentration is not a surprise; it's a confirmation that the radar is picking up the same tide everyone can feel.
The interesting part is the block that doesn't fit the story. Anti-infectives make up a smaller share — about 16% — of a field most investors have quietly written off as unprofitable, yet that block carries two of the sharpest, most concentrated signals on the entire board. When demand accelerates inside a category the market has already discounted, that's precisely the kind of dislocation worth understanding early, because the consensus hasn't caught up to it. The same tension shows up one level down, in the targets themselves: the most-pursued protein is TNF-alpha, a familiar and heavily worked target, but the second is a bacterial enzyme — a reminder that the money is moving in places the standard narrative doesn't look. Each of these veins gets its own deep post in this series.
Three signals hiding in one record
A patent isn't one signal; it's several, layered on top of each other, and reading them apart is where the real intelligence lives. The most obvious is what to make — which specific compounds and chemical scaffolds are drawing sustained, accelerating attention. That's the sourcing question: the molecules heating up now are the ones that will need to be synthesized, supplied, and manufactured next.
The second signal is who is behind it. Every accelerating molecule has organizations standing behind it, and the pattern of who is committing to what is a map of intent — where a large player is doubling down, where a newcomer is planting a flag, where a cluster of filers is quietly converging on the same problem. That's the competitive-intelligence and business-development question: not just what is being built, but by whom, and how seriously.
The third signal is which kind of medicine the demand is flowing into — the modality. Demand doesn't just pick targets; it picks formats. It matters enormously whether the acceleration is happening in classical small molecules, in antibodies, or in the newer degrader and oligonucleotide chemistries, because each modality pulls on a completely different supply chain and set of manufacturing capabilities. Watching where the modality mix shifts tells you which capacity is about to be in demand — and which is about to be idle.
What it means depending on where you sit
The same observation lands differently for everyone downstream of it, because each of them is deciding where to point finite capacity and capital. A leading read on demand is only useful if it changes one of those decisions.
- CDMOs and contract manufacturers — capacity decisions are slow and expensive, and being early to the right chemistry is the difference between a booked line and a stranded one. An accelerating molecule is a demand-side tell about which processes will need capacity before the RFPs arrive.
- API suppliers and specialty-chemical makers — the compounds heating up now define the intermediates, building blocks, and scale-up problems that will be quoted next. Reading the demand curve early is how a supplier positions to be the obvious call rather than a latecomer to a crowded quote.
- Business-development and licensing teams — the map of who is filing around what is a map of partnering opportunities and competitive threats. Seeing a rival converge on a target, or a small player accumulate an unexpected position, is worth knowing before it becomes a press release.
- Investors and strategy — a category accelerating against consensus is exactly the kind of dislocation that repays early attention, well before it shows up in the lagging figures everyone else is watching.
What the signal is — and what it isn't
Honesty about the limits is what makes the rest worth trusting. An accelerating patent signal is a statement about aggregate demand direction — where an industry's attention and investment are visibly concentrating — not a guarantee that any single molecule will succeed. Individual programs fail all the time; that's the base rate of the business. What the radar reads is the tide, not the fate of one boat on it. A compound climbing the curve is a compound the industry is committing to, which is a very different and more reliable thing than a compound that is going to work.
The lead time cuts both ways, too. The same delay that hands us a head start means the record we read reflects filing decisions from some time ago, so this is a directional instrument, not a stock tip. It is best used the way a weather map is used — to see the front coming and position for it — not as a promise about any one day's weather. Read that way, an aggregate demand signal is genuinely rare and genuinely early; read as a certainty about a single name, it will disappoint.
From science to commercial
That's the whole idea. The science of these molecules is well documented; what's hard to see is the commerce — what's heating up, how fast, and who's behind it. That's what we surface, and it's where a discovery becomes a sourcing lead, a competitive-intelligence flag, or a business-development target. Over the next few posts we'll walk the sharpest veins from this week — an antiretroviral surge, the quiet return of antibiotic-resistance chemistry, the kinase race inside oncology, and the map of who's actually filing. We'll show you the observations. The full board is the part we keep.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.